Navigation Links
Medtronic Announces Positive Nine-Month Results for Endeavor,Resolute Next Generation Drug-Eluting Stent at EuroPCR

BARCELONA, Spain--(BUSINESS WIRE)--May 22, 2007 - Professor Ian Meredith, M.D., Monash Medical Centre, Melbourne, Australia, on Tuesday presented positive nine-month results from the Medtronic RESOLUTE clinical trial at the EuroPCR meeting in Barcelona, Spain, with data showing a low number of adverse cardiac events and no protocol-defined stent thrombosis. The next-generation Medtronic (NYSE:MDT) Endeavor(R) Resolute drug-eluting stent system with new BioLinx(TM) polymer is designed to address the special needs of patients who have complex medical conditions and is engineered to match the duration of drug delivery with the longer healing duration often required by these patients.

In clinical results at nine months, the Endeavor RESOLUTE trial showed no Target Lesion Revascularization (TLR), no Target Vessel Revascularization (TVR) and a Major Adverse Cardiac Event (MACE) rate of just 7.0%. Of the trial's 130 patients, 129 (99.2%) received clinical follow-up, and 95 had angiographic follow-up. In-stent late lumen loss, the study's primary endpoint, was 0.22 mm, while in-segment late loss was 0.12 mm. In-stent Angiographic Binary Restenosis (ABR) was 1.0% percent and in-segment ABR was 2.1%.

"What is most impressive about these results is that they occurred in a patient population with complex and challenging characteristics," said Dr. Meredith, the principal investigator of the trial, noting that the average lesion length in the RESOLUTE trial was 15.5 mm and nearly 82% of enrolled patients were classified as having challenging B2/C lesions. "The RESOLUTE trial enrolled a high percentage of patients with lesions that are difficult to treat, including small vessels and long lesions, and these results are extremely promising. Zotarolimus continues to be a very potent drug in preventing restenosis while the new BioLinx polymer appears to be delivering the drug as intended."

Endeavor Resolute leverage
'"/>




Page: 1 2 3

Related medicine technology :

1. Medtronic Updates Long-Term ENDEAVOR I-II Clinical Data Showing Sustained Safety and Significant Reductions in Repeat Procedures
2. Study Supports Cost-Effectiveness of Medtronics Spasticity Treatment for Children with Cerebral Palsy
3. Two-Year Results from the Medtronic ENDEAVOR III Trial Confirm Stents Positive Clinical Profile
4. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
5. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
6. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
9. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
10. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
(Date:12/24/2014)... , Dec. 24, 2014 /CNW/ - ... being recalled after Health Canada tests confirmed it contains ... risks (beta-methylphenethylamine and phenylpropylmethylamine). The distributor, Empire Health Distribution ... the product from retail stores across Canada ... purposes, including for weight loss and increased energy. ...
(Date:12/24/2014)... Mexico , Dec. 24, 2014  Novastem, ... of its first patient in its study for ... the American Stroke Association, ischemic strokes account for ... to enroll qualified patients in the study, entitled ... Administration of Allogeneic Mesenchymal Stem Cells and Intrathecal ...
(Date:12/24/2014)... DUBLIN , Dec. 24, 2014  Actavis ... that the Company has received a complete response ... (FDA) for its New Drug Application (NDA) for ... for the treatment of hypertension.   Photo ... we are disappointed in the receipt of a ...
Breaking Medicine Technology:"Jetfuel Superburn" recalled after Health Canada tests find undeclared drug ingredients 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 2Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 3Novastem Treats First Patient Using Stemedica's Mesenchymal and Neural Stem Cell Combination Therapy for Ischemic Stroke 4Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4
... EntreMed, Inc. (Nasdaq: ENMD ), ... treatment of cancer, today reported results for the ... (Logo: http://photos.prnewswire.com/prnh/20010620/ENMDLOGO) (Logo: http://www.newscom.com/cgi-bin/prnh/20010620/ENMDLOGO) ... for the third quarter of 2010 of ($2.1 ...
... Nile Therapeutics, Inc. (Nasdaq: NLTX ), a ... for cardiovascular disease, today announced its third quarter financial results ... ended September 30, 2010, Nile reported a net loss of ... net loss of approximately $2.0 million, or $0.08 per share, ...
Cached Medicine Technology:EntreMed Reports Third Quarter 2010 Financial Results 2EntreMed Reports Third Quarter 2010 Financial Results 3EntreMed Reports Third Quarter 2010 Financial Results 4Nile Therapeutics Reports 2010 Third Quarter Financial Results 2Nile Therapeutics Reports 2010 Third Quarter Financial Results 3Nile Therapeutics Reports 2010 Third Quarter Financial Results 4
(Date:12/24/2014)... Dennis Thompson HealthDay Reporter TUESDAY, ... have abstained from sex for one year will be allowed to ... that would reverse a 31-year ban on donations from men who ... announced Tuesday its intention to release a new draft guidance in ... from gay men. The FDA is changing its policy based ...
(Date:12/24/2014)... (HealthDay News) -- Researchers say they have used human ... eggs and sperm. While this had already been ... time that these types of cells -- called primordial ... stem cells, according to the team at the University ... germ cells is one of the earliest events during ...
(Date:12/24/2014)... December 24, 2014 For chic ladies, new ... As a part of their Holiday Wish List, Angeldress.co.uk ... as perfect ways to accent ladies’ holiday wardrobe by launching ... should be all over the discount of 80% off, like ... ready to ship. The company’s chic wedding dresses are among ...
(Date:12/24/2014)... There’s a lot going on with The ... now in control of the Senate as well as the ... Act. A lawsuit has been brought against President Obama by ... the ACA have resulted in changes to the law without ... will take place to weigh the validity of subsidies provided ...
(Date:12/24/2014)... December 24, 2014 Attorneys handling talcum ... an update to their website, the Talcum Powder ... between talcum powder class action lawsuits and ovarian cancer ... and ovarian cancer updates at their website, which serves ... for ovarian cancer claims are not the same as ...
Breaking Medicine News(10 mins):Health News:FDA to Lift Ban on Blood Donations by Gay Men 2Health News:FDA to Lift Ban on Blood Donations by Gay Men 3Health News:Angeldress.co.uk Starts Its Big Sales by Offering Various Kinds of Cheap Clothes and Fashion Accessories 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 2Health News:Steven Gerst MD Discusses How, Amid Political Opposition, Court Challenges, and a New Open Enrollment Period, the Affordable Care Act still Relies on Health Informatics 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 2Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 3Health News:Talcum Powder Attorneys Explain Class Action Lawsuits 4
... , , PITTSBURGH , ... grand opening of the first Visionworks® location in western PA. ... thousand private label and designer frames along with contact lenses ... eye care services, Visionworks will debut its first local store ...
... ... who has become an Internet sensation. , ... (PRWEB) February 5, 2010 -- An English ad-man,s overnight verbal outbursts are an ... tips web site SleepBetter.org , says sleep talking is actually quite common and may have ...
... , , LAKE FOREST, Ill. ... Trustmark Mutual Holding Company and Health Fitness Corporation (NYSE AMEX: ... Commission has granted early termination of the waiting period under ... acquisition of HealthFitness. , (Logo:   http://www.newscom.com/cgi-bin/prnh/20090122/CG61641LOGO ) , ...
... ... lion that was first spotted at San Francisco,s famed PIER 39 docks, was successfully rescued, ... Despite rainy skies, a crowd assembled at Rodeo Beach in the Marin Headlands, Sausalito, ... , ...
... , Feb. 5 Food 4 Less Stores is ... hospitals in the communities its stores serve in Southern California ... area. In addition, the supermarket chain,s Foods Co Division is collecting ... , Customers and team members can support their local children,s hospital ...
... TROY, Mich. , Feb. 5 CareTech Solutions ... and services company serving U.S. hospitals and health systems, announced ... newly formed position of vice president, Marketing, Communications and Government ... delighted to have Colleen join the CareTech Solutions team," said ...
Cached Medicine News:Health News:Visionworks(R) Brings High Quality Eye Care & Eye Wear to Cranberry 2Health News:Visionworks(R) Brings High Quality Eye Care & Eye Wear to Cranberry 3Health News:Sleep Expert on "Sleep Talkin' Man:" It Could Happen To Anyone 2Health News:Sleep Expert on "Sleep Talkin' Man:" It Could Happen To Anyone 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 2Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 3Health News:Trustmark and HealthFitness Announce Early Termination of Hart-Scott-Rodino Waiting Period 4Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 2Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 3Health News:Entangled in Fishing Line then Rescued by The Marine Mammal Center - a Sea Lion Goes Back to the Ocean 4Health News:Food 4 Less Charitable Campaign to Benefit Children's Hospitals 2Health News:CareTech Solutions Names Colleen M. Hanley Vice President of Marketing, Communications and Government Affairs 2Health News:CareTech Solutions Names Colleen M. Hanley Vice President of Marketing, Communications and Government Affairs 3
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: